Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes mellitus is associated with a high risk for bone fractures. Although bone mass is reduced, bone quality is also dramatically altered in this disorder. However, recent evidences suggest a beneficial effect of the glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide 1 (GLP‐1) pathways on bone quality. The aims of the present study were to conduct a comprehensive investigation of bone strength at the organ and tissue level; and to ascertain whether enzyme resistant GIP or GLP‐1 mimetic could be beneficial in preventing bone fragility in type 1 diabetes mellitus. Streptozotocin‐treated mice were used as a model of type 1 diabetes mellitus. Control and streptozotocin‐diabetic animals were treated for 21 days with an enzymatic‐resistant GIP peptide ([D‐Ala 2]GIP) or with liraglutide (each at 25 nmol/kg bw, ip). Bone quality was assessed at the organ and tissue level by microCT, qXRI, 3‐point bending, qBEI, nanoindentation, and Fourier‐transform infrared microspectroscopy. [D‐Ala2]GIP and liraglutide treatment did prevent loss of whole bone strength and cortical microstructure in the STZ‐injected mice. However, tissue material properties were significantly improved in STZ‐injected animals following treatment with [D‐Ala2]GIP or liraglutide. Treatment of STZ‐diabetic mice with [D‐Ala 2]GIP or liraglutide was capable of significantly preventing deterioration of the quality of the bone matrix. Further studies are required to further elucidate the molecular mechanisms involved and to validate whether these findings can be translated to human patients. J. Cell. Physiol. 230: 3009–3018, 2015. © 2015 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666 · cited 1×
“Ultimate load, yield load, ultimate displacement, post-yield displacement, stiffness, and total absorbed energy were computerized according to previously published equations (Turner and Burr, 1993).”
MethodIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 1×
“Drucker DJ. 2013.”
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198 · cited 2×
“…incretin receptors on bone cells and alterations of bone microarchitecture in genetically-modified incretin receptor animals (Xie et al., 2005; Tsukiyama et al., 2006; Xie et al., 2007; Yamada et al., 2008; Yabe and Seino, 2012,2013; Gaudin-Audrain et al., 2013; Mieczkowska et al., 2015).”
BackgroundNyman, J. S., Even, J. L., Jo, C.-H., Herbert, E. G., Murry, M. R., Cockrell, G. E., Wahl, E. C., Bunn, R. C., Lumpkin, C. K., Fowlkes, J. L., et al. (2011) · Bone · doi:10.1016/j.bone.2010.12.016 · Cited by 112 · cited 3×
“This protocol contrasts with multiple dose of STZ (40–50mg/kg bw) administered on each of five consecutive days that have previously been used is some animal studies (Motyl and McCabe, 2009; Nyman et al., 2011; Motyl et al., 2012).”
MethodResultMartin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53 · cited 2×
“have been chosen based on our previous studies (Kerr et al., 2011; Martin et al., 2013; Porter et al., 2010).”
MethodSelf-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“In type-1 diabetic models, although liraglutide is less effective than GIP analogues in promoting osteoblast differentiation, it improves tissue material biomechanics by reducing collagen degradation [862].”
BackgroundSelf-citationKillion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Self-citation
Metadata
- Authors
- Mansur, S. A., Mieczkowska, A., Bouvard, B., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2015-08-24
- Volume
- 230
- Issue
- 12
- Pages
- 3009-3018
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2127650366
- Cited by
- 82
- References
- 6
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus. https://app.cochat.ai/papers/10.1002/jcp.25033
- The paper
- Mansur, S. A., Mieczkowska, A., Bouvard, B., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G. (2015). Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.25033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.